Molecular Partners

We are pleased to announce that Philippe Legenne was appointed Chief Medical Officer at Molecular Partners, after serving as acting CMO for the past year.    Under his leadership, the team has successfully progressed the clinical development strategy and execution across Molecular Partners’ entire portfolio, including MP0533, MP0317 and Ensovibep. Now, as CMO, we’re excited to support him as he and our colleagues advance #RadioDARPin therapies towards the clinic.    Read more about Philippe’s appointment and other business updates in our H1 report: https://bit.ly/3yXhHuF   $MOLN #DARPins

Today we announced our corporate highlights and financials for the first half of 2024. Join us as we discuss our results on our conference call tomorrow, Aug 27 at 2:00 pm CET (8:00 am EDT).    Details: https://lnkd.in/efWHEDnq   $MOLN #DARPins #RadioDARPins

We are looking forward to announcing our corporate highlights and financial results for the first half of 2024 on Monday. Dial 1-884-763-8274 (or +41-44-575-0267 for folks in Switzerland) to join the conference call at 2:00 pm CET (8:00 am EDT) on Tuesday, Aug 27.    $MOLN #DARPins #RadioDARPins 

We focus on creating unique #DARPin solutions for major medical challenges. MP0533 shows our strategy at work against acute myeloid leukemia (#AML), an aggressive cancer with a high relapse rate. MP0533 is a tetra-specific molecule that strongly prefers binding to AML cells over healthy cells through the combined targeting of three surface antigens that are mostly only found together on AML cells. Combined with binding to the immuno-stimulator CD3, the net effect is a powerful directed immune attack with high specificity for AML cells. The goal? Better clearance of AML cells with less risk to healthy cells – a clear match for the medical need in many AML patients today. For more information about MP0533 and our other #cancer therapies in development, see https://bit.ly/46erfgS #biotech

Proudly founded in Switzerland with global collaborations and international team members, for us #SwissNationalDay is a special day on the calendar. Beyond the mountains and chocolate, Switzerland is one of the world’s greatest biotech hubs – in fact, biotech & pharma contribute ~40% to Switzerland’s exports! More: https://bit.ly/3LAZcyK #SwissBiotech

Summer is in full swing here in Zürich! At our annual summer social event, we were able to soak up the sun, enjoy each other’s company and celebrate team members who have been a part of Molecular Partners for the past 15 years. We have many colleagues who have been here since the early days of the company, and we appreciate all of their contributions to our innovative science and people-first culture.    See here for more info about what life is like at MP: https://bit.ly/3Wwd7wq

Seen our name but curious for an overview of exactly who we are and what we do? Well, we are a clinical-stage biotech company of approximately 180 people dedicated to pioneering a new class of medicines, #DARPin therapeutics, for patients. Through our leadership and alongside partners, we have:    🔹 Developed 7 clinical-stage DARPin candidates 🔹 Treated >2500 patients globally  🔹 Demonstrated clinical value of DARPin therapeutics across several therapeutic areas 🔹 Reached late-stage clinical development, including registrational stage   Learn more about us and our science through our one-pager: https://bit.ly/3zy4acW   #RadioDARPins #SwitchDARPin #cancerresearch #radiopharmaceuticals

Riding our bikes to work helps us get into high gear at the office! Over the past two months, we’ve enjoyed taking part in the #BikeToWork challenge, the largest bike and health promotion campaign in Switzerland. Thank you to all who participated, who together biked an impressive 8803 km!

Last month at #SNMMI we debuted our first #RadioDARPin therapeutic (RDT) candidate, MP0712, in co-development with Orano Med. 212Pb-labeled MP0712 is designed to precisely target DLL3-expressing tumor cells and is being developed for small cell lung cancer patients. Learn more about “Our DARPin Approach to Radiopharmaceuticals” in this blog by Daniel Steiner, SVP Research & Technology.

This week Molecular Partners is at the Gordon Research Conferences Radionuclide Theranostics for the Management of Cancer to share insights about our #RadioDARPin Therapy (RDT) platform and our first RDT candidate, MP0712, targeting DLL3 in small cell lung cancer a 212Pb-labeled and DLL3-targeting RDT for small cell lung cancer patients in co-development with Orano Med.    Join Michael Stumpp, EVP Projects, for his talk on July 10th at 9:00 AM ET and Alessandra Villa, Director Lead Generation, for her poster on July 11th at 4:00 PM ET to learn about our progress.   View the full conference agenda here: https://bit.ly/3zaIPpB